Bharat Jasani, MD

Prof. Bharat Jasani joins Targos as Director of Pathology.

Professor Bharat Jasani

In order to strengthen the in-house pathology capacities and expertise, Targos today announced, that Prof. Bharat Jasani BSc (Hons), PhD., MBChB, FRCPath will join the company as Director of Pathology. Prof. Jasani, who was already consultant pathologist for Targos and has been a member of the scientific advisory board for several years has an outstanding research record in cancer biomarkers. As the Head of Biomarker Analysis Unit, Department of Cellular Pathology, Cardiff & Vale Local Heath Authority, he led strategic plans to modernize histopathology service, and the development and establishment of diagnostic immunocytochemistry & molecular pathology service in Cardiff and Wales. Over the past 10 years he has also promoted quality assurance and standardization of cancer biomarker analyses as the Breast Cancer Module Leader of UKNEQAS of ICC, the UK’s lead member to the International Working Group on Standardization of Breast Cancer Biomarking, as well as International Advisor to the United States Sub-Committee on Quality Assurance for Immunocytochemistry. As the Principal Investigator and Co-investigator for several major translational research projects targeted at developing predictive biomarkers for colorectal and breast cancer, he has been invited to act as a Consultant and a Key Opinion Leader to several world's leading biotech companies. He as published over 200 peer reviewed articles including in The Lancet; Nat Rev Clin Oncol; J. Immunology; Am J Clin Pathol; J of Pathology & Seminars in Cancer Biology.


Prof. Jasani joins Targos after being Chairman at the Department of Biomedical Sciences: Nazarbayev University. Astana, Republic of Kazakhstan and  Adjunct Professor of Pathology: University of Pittsburgh School of Medicine, Pittsburg, PA: USA. Together with the existing pathology team lead by the Targos Chief Medical Officer, Prof. Josef Rüschoff and the large international network of consulting pathologists, Targos will be prepared to take on the challenge of the increasing demands for high quality pathology in biomarker development, central testing as well as training and education.